anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A new class of solid pharmaceutical formulations enables the attainment of slow, zero order in vivo release of a wide range of pharmaceutically active ingredients upon oral administration. A broad range of release rates can be preselected by suitable adjustments of tablet properties. The formulations are based upon control of active ingredient release from the surface of the tablet via a controlled surface erosion mechanism. These compositions comprise:(a) an effective amount in the range of 10-90 wt. % of a pharmacologically active compound having a water solubility (20' C.) of 1/5-1/1000 (w/w);(b) 1-40 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20° C.) of 1/1-1/40 (w/w);(c) 2-20 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20° C.) of 1/1-1/10 (w/w);(d) an amount in the range of 0.05-1.0 wt. % of a disintegrating agent for pharmaceutical compositions, at which amount the compound is ineffective as a disintegrating agent;(e) 0.1-2.0wt.. % of a surfactant which is pharmaceutically acceptable in oral compositions; and, as necessary for tablet manufacturing purposes;(f) 1-20 wt. % of a binder which is pharmaceutically acceptable in oral compositions; or(g) 0.5-5.0 wt. % of a die wall lubricant which is pharmaceutically acceptable in oral compositions.
An audiometric testing system containing a processor and programmable analog circuitry for controlling frequency and intensity of audiometric test tones communicates with a remote data processing system via a communications link. The remote data processing system stores prior audiometric records for a large number of subjects. Each day, the audiometric records of a number of selected persons are transmitted from the remote data processing system to a memory of the audiometric testing system in response to identification numbers entered by an operator. The audiometric responses of each person to patterns of sounds of varying frequencies and intensities are determined. The varying frequencies and intensities are determined by a bracketing subroutine of an algorithm stored in and executed by a processor of the audiometric testing system. A person's responses to such test tones are utilized by the bracketing subroutine to determine his threshold levels at the respective frequencies for each ear. The algorithm automatically computes the pure tone averages for each ear from the threshold levels at a plurality of predetermined frequencies. The algorithm also automatically computes the binaural hearing impairment based on test results from prior testing of the person. Any significant shift in threshold is determined by comparison with the prior test results. The audiometric testing system includes a printer which prints the persons' complete hearing test record, including relevant identifying information, present test results, pure tone averages, binaural hearing impairment, significant threshold shifts, and a recommended time for the next testing. After all persons have been tested for the day, their updated audiometric records are transmitted via the communications link to the remote data processing system.
After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
This is a prospective, randomized trial of two experimental treatments, prednisolone + mycophenolate mofetil and prednisolone + rilonacept, in comparison with standard of care, in patients with alcoholic hepatitis. Patients will start therapy with prednisolone. At Day 8 response to prednisolone will be determined using the Lille score. Patients with a Lille score ≥ 0.45 will be randomized to standard of care (continue prednisolone, stop all therapy and/or offer palliative care) or to have prednisolone continued and mycophenolate added for the next three weeks. Patients with a Lille score \<0.45 will be randomized to continue prednisolone alone (standard of care) or to have rilonacept added to their treatment regimen (experimental group) for the next three weeks. Patients will complete follow-up visits at Week 12 and Week 24.
PURPOSE:The titled composition useful as setting lotion, hair spray, styling agent, etc., using both a high polymer compound and a polysaccharide, having synergistic action of the components and improved set retention properties and providing the hair with a good feeling. CONSTITUTION:A hair cosmetic composition using both a high polymer compound (e.g. cationic high polymer compound such as cationic cellulose, etc., anionic high polymer compound such as ethyl acrylate-acrylic acid amide-acrylic acid copolymer, etc., ampholytic high polymer compound such as metacrylic acid ester copolymer, etc., and nonionic high polymer compound such as polyvinylpyrrolidone, etc.) and a polysaccharide (e.g. lipopolysaccharide which can be produced by a bacterium belonging to the genus Acinetobacter, etc.) in a weight ratio of preferably 1:0.02-2.
The compound 2-diethylaminoethylchloridehydrochloride(DEAECHC) is used in the pharmaceutical industry, in particularfor the preparation of isothioronic salt,2-diethylaminoethanethiol anddiethylamineethanethiolhydrochloride. The method for itspreparation includes reaction between 2-diethylaminoethanol andthionylchloride in an organic solvent with high yield and purity.2-diethylaminoethanol is fed to a thionylchloride solution inchloroform at temperature range from 30 to 40°C for 1-2 h., it isadditionally agitated for 1-2 h. at the same temperature and afterthat the temperature is raised to 65-70°C for the separation ofthe dioxide produced. There follows separation of the chloroformand unreacted thionylchloride and their return to the subsequentsynthesis as return chloroform. The reaction mass is subjected torecrystallization of the DEAECHC, and ethyl or methyl alcohol oranother organic solvent is added to it which dissolves theimpurities, purifying the product. The produced DEAECHC crystalsare subjected to filtration and drying, and the filtrate isdistilled for the separation of the ethyl alcohol and itrecrystallizes with ethyl alcohol and diethyl ether or is returnedagain to the subsequent cycle of the DEAECHC recrystallizationstage. The purity of the products is 97-98% and its yield is94-96.1 claim
FIELD: magnetometric imaging. SUBSTANCE: invention relates to magnetometrically producing human and animal body images utilizing, as diagnostic reagent, lipid-coated physiologically acceptable corpuscular FERROMAGNETIC or ferromagnetic material into gastroenteric tract, reproductive tract, urinary duct, any closed body cavity, and musculature. Magnetic field deviations in body are thereby detected by the aid of squid magnetometer. To form reference image, magnetic-resonance image of body is created. When magnetometric image of lymph node is formed, dextran-coated particles are used. EFFECT: increased localization efficiency. 4 cl, 3 dwg
INTRODUCTION: Cyclic vomiting syndrome (CVS) is a disorder of gut-brain interaction often triggered by stress. Interventions such as meditation may improve psychological outcomes and health-related quality of life (HRQoL), but their efficacy and the underlying mechanism are unknown.
METHODS: We conducted a 6-week single-arm pilot study to assess the effects of heartfulness meditation (HFM) in CVS using a custom-designed meditation app. Primary outcomes included state and trait anxiety and mood state changes pre vs post-meditation, and secondary outcomes were psychological distress, coping, sleep quality, and HRQoL at baseline and at weeks 3 and 6. Serum concentrations of endocannabinoids N -arachidonylethanolamine and 2-arachidonoylglycerol and related lipids were measured pre- and post-HFM at baseline and week 6.
RESULTS: In 30 treatment completers, there was a significant improvement in state anxiety ( P < 0.001), total mood disturbance ( P < 0.001), and other mood states (all P values < 0.05) across the 3 time points. Trait anxiety was also improved at week 6. There was a significant improvement in psychological distress (Global Severity Index), sleep quality (daytime dysfunction), coping (using religion/spirituality), and HRQoL (mental and physical) across the 3 time points (all P < 0.05). Significant increases in N -arachidonylethanolamine and related lipids N -oleoylethanolamine and palmitoylethanolamide post vs pre-HFM were observed at week 6 ( P < 0.001, 0.002, 0.003, respectively). No adverse effects were noted.
DISCUSSION: App-delivered HFM is feasible, safe, and effective and improves psychological outcomes and augments endocannabinoids. This provides insight into the mechanism underlying HFM and has potential for widespread use as a digital therapeutic in CVS and other disorder of gut-brain interaction.
Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
The food supplement for combating asthma contains certain nutrients such as vitamins, minerals and unsaturated fatty acids that combat infections and inflammations of the respiratory system, soothe and act favourably on dilation of the bronchi, and provide relief to persons suffering from breathing difficulties caused by congestion or lack of air. The asthma combatting component plays a very important role in antioxidant enhancement and thus improves the ability of the body to resist a large number of diseases and, in particular, asthma. The novel composition is characterised in that it contains, in a finely powdered mixture, gum arabic, linseed, white candi sugar, fenugreek seed and liquorice. This food supplement acts in a gentle manner without attacking the organism and without side effects, and allows use by oral administration over a prolonged period of three to twelve months, depending on the condition of the patient, in both children and adults. For adults, the dose is the equivalent of 2 capsules (approximately 1.50 grams) in the morning, on an empty stomach (20 to 30 minutes before breakfast) and the equivalent of 2 more capsules in the evening, before bed. Children should take the equivalent of half this dose.
The disclosed conformable coating provides a highly durable and resilient film useful for protecting and repairing surfaces such as skin and mucous membranes. The coating comprises 0.1% to 65% wt. of a polymerized cyanoacrylate monomer and at least 35% wt. of an elastomer phase. The conformable coating composition comprises a polymerizable cyanoacrylate monomer, an elastomer, and a volatile liquid. The cyanoacrylate monomer is 0.1 to 65% wt. of the nonvolatile portion, the elastomer in an elastomer phase is at least 35% wt. of the nonvolatile portion, and the volatile liquid is at least 40% wt. of the total composition.
The present invention discloses polyester and a preparing method thereof, wherein the polyester contains an active medicine, and a main chain contains amino acids. The active medicine is polyester which has a right structure general formula in which R#-[1] represents serine, an aspartic acid, a glutamic acid or lysine, and R#-[2] represents a medicine having a reactive group. The preparing method comprises polymerization and de-protection of lactide or lactone and a morpholine dione derivative and bonding of the lactide or the lactone and the medicine; the morpholine dione derivative has a polyfunctional group amino acid. The natural polyfunctional group amino acid is irregularly introduced into biodegradable polyester; thus, the antigenicity of degraded products is avoided, and the degraded products can be completely biologically absorbed. The polyester contains active groups, such as a carboxyl group, a hydroxyl group, an amino group, etc.; obtained medicinal high molecules can directly work and can work after degraded. The present invention can be used as a coating layer of a medical appliance; as well as improving the biocompatibility of the medical appliance, the present carries purposive medicines, and thus, the purpose of providing medicines continuously is achieved. The present invention can be also made into implantation bodies or other preparations.
INTRODUCTION: A growing body of scientific evidence shows that simulation-guided auscultatory training can significantly improve the skills of medical students. Nevertheless, it remains to be elucidated if this training has any long-term impact on auscultatory skills. We sought to ascertain whether there were differences in heart and lung auscultation among residents who received simulation-guided auscultatory training before graduation vs. those who did not.
MATERIALS AND METHODS: A total of 43 residents were included in the study; 20 of them entered into Cardiology specialty school (C) and 23 of them entered into Internal and Occupational Medicine specialty schools (M) at the University of Trieste. Based on the history of simulation-guided auscultatory training before graduation (yes = Y; no = N), four groups were formed: CY, CN, MY, and MN. Residents were evaluated in terms of their ability to recognize six heart and five lung sounds, which were reproduced in a random order with the Kyoto-Kagaku patient simulator. Associations between history of simulation training, specialty choice and auscultatory skills were evaluated with Kruskal-Wallis test and logistic regression analysis.
RESULTS: Auscultatory skills of residents were associated with simulation-guided training before graduation, regardless of the specialty chosen. Simulation-guided training had a higher impact on residents in Medicine. Overall, heart and lung sounds were correctly recognized in 41% of cases. Logistic regression analysis showed that simulation-guided training was associated with recognition of aortic stenosis, S2 wide split, fine crackles, and pleural rubs. Specialty choice was associated with recognition of aortic stenosis as well as aortic and mitral regurgitation.
DISCUSSION: History of simulation-guided auscultatory training was associated with better auscultatory performance in residents, regardless of the medical specialty chosen. Choice of Cardiology was associated with better scores in aortic stenosis as well as aortic and mitral regurgitation. Nevertheless, overall auscultatory proficiency was quite poor, which suggests that simulation-guided training may help but is probably still too short.
Inflammatory skin diseases are typically managed with semi-solid formulations such as creams and ointments. These treatments often fail to remain on the skin for long, as they can be easily wiped off by clothing, necessitating frequent reapplication throughout the day and resulting in poor patient adherence. Therefore, this study sought to fabricate an electrospun dressing as an alternative dosage form that provides a sustained release of the anti-inflammatory agent tofacitinib over three days. In this study, three types of electrospun fiber dressings - uniaxial, coaxial, and layer-by-layer - were produced and examined for their morphological, mechanical, and release characteristics. In addition to a comprehensive characterization, another objective was to analyze the drug permeation behavior from these fiber dressings on porcine skin, comparing their performance to that of a tofacitinib cream. The layer-by-layer system notably exhibited a delayed drug release, while the uniaxial and coaxial systems demonstrated an initial burst release. However, the permeation studies revealed no significant differences between these systems, underscoring the necessity of conducting such studies - a crucial aspect often overlooked in research on electrospun fiber dressings. Overall, this study highlights the potential of electrospun, drug-loaded dressings for the treatment of inflammatory skin diseases.
The present disclosure provides methods and compositions related to the combination therapy of a macrophage-directed immunotherapy and a cytokine (e.g., IL-10). The combination of the macrophage-directed immunotherapy and a cytokine is useful in treating and/or preventing cancer (e.g., lung cancer) in a subject. Therapies that activate macrophages are emerging in cancer immunotherapy. One potential therapeutic target is the CD47-SIRPa, interaction, which acts as a myeloid immune checkpoint. Cluster of Differentiation 47 (CD47) is highly expressed on many different types of cancer cells, including lung cancer cells. CD47 binds to an inhibitory receptor, signal regulatory protein alpha (SIRPa,), that is expressed on the surface of macrophages and other myeloid immune cells.
Ephrin B3, a member of Eph/ephrin family, contributes to embryogenesis and carcinogenesis, but few studies have suggested whether this ligand has regulatory effect on colitis. This study was to determine whether ephrin B3 played a role in colitis and colonic carcinogenesis. Dextran sodium sulfate (DSS)-induced colitis and azoxymethane (AOM)/DSS-induced colitis-associated carcinogenesis model was established in Efnb3-deficient (Efnb3-/-) mice. Label-free quantitative proteomics were performed to identify the Efnb3-regulated proteins. Our results showed that Efnb3 knock out reduced the symptoms of DSS-induced colitis, such as disease activity index (DAI), inflammatory factors release, and dysfunction of the intestinal barrier. Quantitative proteomics revealed that Efnb3 regulated 95 proteins which clustered in the platelet degranulation, response to elevated platelet cytosolic Ca2+, MAPK signaling for integrins such as ITGB4. Furthermore, ephrin B3 inactived ITGB4/AKT signal pathway and then promoted epithelial barrier dysfunction. Simultaneously, ephrin B3 promoted Gremlin-1/NF-κB signal pathway and thereby increased inflammatory factors release. In addition, the higher level of Efnb3 in colon cancer patients is correlated with worse survival. Efnb3-/- mice exhibited susceptibility to AOM/DSS-induced colorectal cancer. Our finding discovered that Efnb3 played an important role in the development of colitis and colitis-associated colorectal cancer. Efnb3 deficiency improved the intestinal barrier by ITGB4 and suppressed inflammation via Gremlin-1/NF-κB signal pathway, which may provide a novel therapeutic strategy for the treatment of colitis and colitis-associated colorectal cancer.
When a stationary target is briefly presented on top of a moving background as it reverses direction, the target is displaced perceptually in the direction of the upcoming motion (the flash grab effect). To determine the role of attention in this effect, we investigated whether the predictability of the location of the flash grab target modulates the illusion. First, we established that effect was weaker for spatially predictable targets. Next, we showed that the flash grab effect decreased for a narrower spatial spread of attention before the onset of the target and that it was smaller for left hemifield presentations than right. Finally, we demonstrated that diverting attention away from the target and the background motion decreases the flash grab effect. In the first two experiments, the decrease in the illusion could be attributed to either increased attention to the target or decreased attention to the motion; we assume that increasing attention to the target necessarily decreases attention to the motion. However, in the final experiment, the central task decreases attention to both the target and the motion. The results show a decrease in the illusion and that reveals that attention to the motion is the primary causal factor.
PCT No. PCT/FI92/00274 Sec. 371 Date May 5, 1994 Sec. 102(e) Date May 5, 1994 PCT Filed Oct. 15, 1992 PCT Pub. No. WO93/07858 PCT Pub. Date Apr. 29, 1993.This invention describes a device for peroral administration of a therapeutic agent which is capable of existing in an unionized therapeutically active form. The device comprises a reservoir comprising the therapeutic agent in ionized form, which reservoir has a wall permeable to un-ionized material and impermeable to ionized material; and a solid material which upon uptake of water is converted to a buffer; the solid material having, on uptake of water, a pH which determines the rate of permeation of the therapeutic agent in un-ionized form through the reservoir wall. The device enables the release of the therapeutic agent to be controlled by the pH of the buffer and, if desired, the composition of the reservoir walls. The composition of the surrounding aqueous medium does not affect the rate of release.
The present invention is directed to a vector and its use to generate genetically modified animals and cells. One aspect of this invention involves a vector that comprises a sperm cell and one or more polynucleotide molecules bound to a sperm cell through one or more non-liposome based linkers. The sperm cell can be any animal sperm cell, preferably non-human animal. In one preferred embodiment of this invention, the one or more polynucleotide molecules encode for a gene product that confers desired characteristics in the cells or the animals. In another preferred embodiment of this invention, the linker is a protein or polypeptide, preferably sperm specific such as an antibody that binds with the external surface of the sperm cell. The linker interacts with one or more polynucleotide molecules preferably by ionic interaction. This interaction can also be carried out by different molecular interactions, including the use of another or secondary linker. The association of the sperm, linker, and the one or more polynucleotide can also occur in vitro or in vivo. In another aspect of the present invention genetically modified cells or animals are derived from the fertilization of an animal egg cell with the vector described above. Fertilization can occur in vitro or in vivo. In one preferred embodiment, genetic modification occurs with the polynucleotide molecule integrating, wholly or partially, into the cell or animal's genome. Another aspect of the present invention includes cells, such as sperm cells or egg cells, and cell lines that are derived from these genetically modified animals or their descendants. In another aspect of the present invention, the genetically modified animals derived from the use of the sperm vector described above possess certain desired characteristics.
Lung cancer patients from both the intervention and the control group will complete validated questionnaires at baseline and then after 3, 6, 9, 12, 15 and 18 months (or until death for those with a survival of less than 18months) to assess their perceived collaboration between their FP and the oncology team (from an adaptation of Nielsen et al.'s validated questionnaire (2003)), their quality of life (from the EORTC-QLQ-C30), pain and other symptom relief (from the EORTC-QLQ-LC13), their level of distress, anxiety and depression (from the HADS), their self-efficacy (from an adaptation of Lorig et al.'s validated questionnaire (1996)). Several processes of care will also be measured at the same intervals: number of exchanges of information, number of visits to FP, number of answered/unanswered calls from FP, delay to return patients' calls, responsibility for care by FP at the terminal phase of cancer, service utilization (ER visits, hospitalization, community health services). The investigators will also measure in patients' principal family caregivers, their perceived collaboration between FP and the oncology team (same questionnaire than the one used for patients but adapted to family caregivers), their distress (from the IDPESQ), psychological burden (from the CBS-EOLC) and self-efficacy (same questionnaire than the one used for patients but adapted to family caregivers . Finally, measures related to FP will include their perceived collaboration with the oncology team (same questionnaire than the one used for patients and family caregivers but adapted to FPs).